Posts that will appear within the SRF Blog
Michael Greve, founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures, announced today that he will make an additional €300 million ($361m USD) available to launch new rejuvenation biotechnology startups and support the clinical translation of therapies designed by Kizoo’s existing portfolio of companies.
SRF’s Chief Science Officer, Dr. Aubrey de Grey, recently estimated a 50% chance that aging could be brought under medical control in as little as 15 years’ time. In a new interview with NextBigFuture, Dr. de Grey explains how recent developments – including the global response to the COVID-19 pandemic – contributed to that prediction.
At the end of 2020, we invited all our supporters to submit designs for an official SRF mask. As well as being worn by our staff, these masks are now available – while supplies last – to anyone who’d like to support our work to end age-related disease and disability.
“I think there is at least a 50/50 chance that most people alive today will live to 1,000 years old.” In a new video produced by WebMD.com, Dr. Aubrey de Grey discusses emerging medical technologies that could not only pause aging, but reverse it, in the surprisingly near future.
The MitoSENS team has recently published a new protocol which enables researchers to isolate mitochondria from mammalian cells more efficiently and scalably than any prior technique, using only readily available and economical reagents and equipment.
At the end of each year, SRF launches our final fundraising campaign – the aptly named End of Year Campaign – to encourage our donors to donate during the most giving time of year. This year, matching funds from Michael Antonov and a team of other supporters helped you to smash through our original goal.
At the end of each year, SRF launches our final fundraising campaign – the aptly named End of Year Campaign – to encourage our donors to donate during the most giving time of year. This year, matching funds from Michael Antonov and a team of other supporters helped you to smash through our original goal.
In heterochronic parabiosis, joining the circulatory systems of young and old mice causes the older animal to recover some features of youth. The effect has been widely assumed to be driven by pro-youth factors in younger blood, but an alternative hypothesis is possible: that the procedure is instead diluting pro-aging factors in the older partner.
Elie Dolgin’s recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
We are pleased to announce that the ApoptoSENS team led by Dr. Amit Sharma at the SRF Research Center has recently been granted a Catalyst award, courtesy of the Healthy Longevity Global Competition, to continue and expand their critical work on the interactions between senescent cells and natural killer (NK) cells.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
